retatrutide peptide fda approval Status 2026: Everything We Know So Far A review of an investigational

12 , R33 (2010)

Non-arteritic anterior ischemic optic neuropathy (NAION) is characterized by optic nerve ischemia leading to abrupt vision loss, yet its pathophysiology remains inadequately understood [96]

After approving oral Wegovy in December 2025, the FDA has now also approved Clinical trial data shows that participants taking Foundayo achieved meaningful weight loss compared with placebo, reinforcing its potential as an effective treatment option

For additional options, view our full range of research products available in Canada.

JH: Conceptualization, Funding acquisition, Visualization, Writing review and editing

For injections, side effects often improve after a few weeks as your body adjusts